Published in final edited form as:

Clin Ther. 2016 April ; 38(4): 716–732. doi:10.1016/j.clinthera.2016.01.006.

Prevention of Necrotizing Enterocolitis Through Manipulation of the Intestinal Microbiota of the Premature Infant

Kannikar Vongbhavit, MD^{1,2} and Mark A. Underwood, MD²

¹ Department of Pediatrics, HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakornayok, Thailand ² Department of Pediatrics, University of California Davis, Sacramento CA

Abstract

In spite of four decades of research, necrotizing enterocolitis (NEC) remains the most common gastrointestinal complication in premature infants with high mortality and long-term morbidity. The composition of the intestinal microbiota of the premature infant differs dramatically from that of the healthy term infant and appears to be an important risk factor for NEC. Promising NEC prevention strategies that alter the intestinal microbiota include probiotics, prebiotics, synbiotics, lactoferrin, and human milk feeding.

Keywords

human milk; probiotic; prebiotic; synbiotic; lactoferrin; necrotizing enterocolitis; premature infant

Introduction

Necrotizing enterocolitis (NEC) is a common and devastating disease of premature infants. It affects approximately 7% of infants weighing between 500 and 1,500 g with mortality rates as high as 30%¹. The pathophysiology of NEC has been an area of active study for four decades. Current thinking suggests that NEC is not a single disease or infection but the final pathway of a variety of insults. Risk factors include prematurity of the innate and adaptive immune responses (e.g. a poorly regulated inflammatory responses and alterations in intestinal permeability, motility, apoptosis, and autophagy), enteral feeding, an altered intestinal microbiota and variation in intestinal perfusion¹⁻³. The current clinical staging of NEC was initially proposed by Bell⁴ and modified by Walsh⁵ and has endured for three decades. The challenges of this classification include disagreements among experts as to the clinical relevance of stage 1 NEC (resulting in variation in inclusion of stage 1 NEC in

Corresponding author: Mark A Underwood, Division of Neonatology, 2516 Stockton Blvd, Sacramento, CA 95817 USA, phone 01-916-734-5779, FAX 01-916-456-2236, munderwood@ucdavis.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest: none

reports of clinical trials and cohort studies), the lack of distinction between NEC and spontaneous ileal perforation without necrosis, and a lack of evidence regarding applicability to term infants with NEC. Treatment of NEC has changed little over the decades: bowel rest, broad-spectrum antibiotics, parenteral nutrition, with support of ventilation and blood pressure and either peritoneal drainage or resection of necrotic bowel in severe cases. There is significant short-term morbidity, including abnormal bowel function, prolonged parenteral nutrition requiring central line placement, and longer lengths of stay in hospital with significantly higher costs⁶. Long term morbidity includes poor growth, malabsorption and delays in neurodevelopment⁷.

Two compelling observations shed light on the pathogenesis of NEC. First, the onset of NEC is generally at 2-6 weeks of life and tends to occur later in the most premature infants with the highest risk of NEC at 29-33 weeks corrected gestational age⁸. This observation supports the hypothesis that a certain level of “maturation” of the immune system is required for NEC pathogenesis. It is likely not coincidental that the Paneth cells of the small intestine become functional at about this time. These sentinels of the crypts of Lieberkuhn shape the composition of the intestinal microbiota and protect the intestinal stem cells from injury^{9, 10}. Second, small but carefully performed studies demonstrate alterations in the intestinal microbiota prior to the onset of NEC. The term dysbiosis implies an alteration in the composition of the intestinal microbiota and/or microbiome related to disease. Independent investigators have demonstrated that an early predominance of Firmicutes (particularly Clostridiaceae) in the first weeks of life predisposes to NEC and that a sudden bloom of Proteobacteria (particularly Enterobacteriaceae) is common in the days just prior to the onset of NEC¹¹⁻¹⁴. The latter observation is particularly compelling in light of the capacity of several Enterobacteriaceae to trigger an inflammatory response and then outcompete other commensal bacteria by selective consumption of the products of inflammation¹⁵. In this article, we will touch briefly on the causes of dysbiosis in the premature infant and review the efficacy of attempts to prevent NEC by dietary interventions designed to correct dysbiosis including probiotics, prebiotics, synbiotics, lactoferrin, and human milk.

Gut colonization and dysbiosis in premature infants

For many years, accepted dogma maintained that the *in utero* environment was sterile and that the intestinal tract of the fetus was not colonized with bacteria until the time of rupture of membranes. Recent studies suggest that the fetal membranes are not impermeable to bacteria and that many fetuses are exposed to microbes in the amniotic fluid before delivery¹⁶⁻¹⁸. The impact of this early exposure is unclear. While early colonizers of the infant gut are heavily influenced by mode of delivery¹⁹, the “second wave” of colonists in term infants is mostly determined by feeding type with breast fed infants dominated by bifidobacteria and bacteroides and formula fed infants dominated by streptococci, staphylococci and lactobacilli²⁰. The “second wave” of gut colonists in premature infants is less influenced by type of feeding and differs markedly from that of term infants with high numbers of Clostridiaceae and Enterobacteriaceae and relatively low numbers of Bifidobacteriaceae and Bacteroidetes²¹⁻²⁵. Perhaps the most important influence on the composition of the premature gut microbiota is degree of prematurity²⁶. The use of acid suppressive medication delays intestinal transit time, alters the intestinal microbiota²⁷ and

increases the risk of NEC²⁸. In addition, antibiotic administration leads to changes in the composition of the gut microbiota, suppressing growth of both commensal and pathogenic bacteria, and increases the risk of NEC^{25, 29, 30}. In spite of (or perhaps in part related to) aggressive cleaning protocols, the NICU environment is an important source of pathogenic organisms and influences intestinal colonization of infants with prolonged hospitalizations³¹. Other potential influences on the intestinal microbiota of premature infants include duration of feeding tubes, kangaroo skin-to-skin care, periods of gut rest, administration of colostrum to the buccal mucosa³² and genetic factors (e.g. common mutations in the FUT2 gene)^{33, 34}. Among the many factors predisposing to dysbiosis in premature infants, those with clear associations with NEC include degree of prematurity²⁶, formula feeding³⁵, antibiotics^{29, 36}, and acid-blocking agents²⁸. The concept of altering the intestinal microbiota or correcting dysbiosis to decrease risk of NEC is promising. We will review five overlapping strategies: probiotics, prebiotics, synbiotics, lactoferrin and human milk (Figure 1).

Probiotics

Probiotics are biological formulations or dietary supplements containing living microorganisms, most commonly one or more of the following genera: *Bifidobacterium*, *Lactobacillus*, *Streptococcus*, *Escherichia*, or *Saccharomyces*^{37, 38}. Most currently available probiotics were selected because of their ease of production, stability, or food-preservative properties, rather than based on a specific mechanism of disease prevention. Mounting evidence suggests that in addition to influencing the composition and diversity of the intestinal microbiota, probiotic microbes influence the host innate and adaptive immune systems through a variety of mechanisms. Many of these mechanisms appear to be species, subspecies, or even strain specific. For example, three species of *Bifidobacterium* decrease incidence and severity of NEC in animal models³⁹⁻⁴¹ but appear to utilize different mechanisms: *B. longum* subsp *infantis* attenuates induction of IL6, IL8, TNF α and IL23 in the rat NEC model³⁹, decreases IL1 β induced IL8 and IL6 expression in immature human gut xenografts⁴², and has a competitive advantage over other gut microbes in the presence of human milk oligosaccharides⁴³; *B. bifidum* improves barrier function⁴⁴, decreases apoptosis⁴⁵ and attenuates IL6 induction in the rat NEC model⁴⁰ and alters short chain fatty acid production *in vitro* in feces from premature infants⁴⁶; and *B. breve* decreases inflammation in the rat NEC model⁴¹ and alters butyrate production⁴⁶ and increases serum levels of TGF β expression in premature infants⁴⁷. Lactobacilli also show diversity of function with 3 species that decrease NEC in animal models⁴⁸⁻⁵⁰ with different mechanisms: *L. acidophilus* secretes one or more molecules that inhibit induction of inflammation by platelet activating factor⁵¹ and alters expression of hundreds of genes important in apoptosis, angiogenesis, and immune response⁵²; *L. reuteri* decreases expression of IL6 and TNF α and increases ileal regulatory T cells in the rat NEC model⁵³ and increases intestinal motility⁵⁴; *L. rhamnosus* (strain GG, ATCC 53103) decreases expression of TNF α and MIP2 through upregulation of the IL10 receptor⁵⁵ and decreases intestinal permeability⁵⁶ through both increased expression of tight junction proteins⁵⁷ and decreased apoptosis⁵⁸, while a different strain (HN001) decreases incidence and severity of NEC in both a mouse and a piglet model, through alterations in TLR9 signaling⁴⁹.

Multiple randomized placebo-controlled clinical trials (RCT) and cohort studies of probiotics in premature infants have been performed. A recent meta-analysis of 20 RCTs found probiotics to decrease the risk of NEC (OR 0.43, 95% CI 0.31-0.56) and death (OR 0.65, 95% CI 0.52-0.81) in this high risk population³⁷. A meta-analysis of 12 cohort studies including more than 10,000 premature infants found similar rates of protection (RR for NEC 0.55, 95% CI 0.39-0.78 and RR for death 0.72, 95% CI 0.61-0.85)⁵⁹. Tables 1⁴⁷, 60-91 and 2⁹²⁻¹⁰¹ summarize English language RCTs and cohort studies in premature infants that included NEC, sepsis, or death as a reported outcome. The recent publication of the much awaited PiPS trial⁶⁰ which showed no improvement in NEC, sepsis, or mortality in 1315 premature infants with gestational age 23-30 weeks randomized to receive either *B. breve* (strain BBG-001) or placebo underscores the importance of determining the best species and strain of probiotic for NEC prevention and that this choice may differ based on populations and genetics. Clinical trials comparing probiotic species or strains in premature infants are needed. Given the significant challenges, including the large required sample size and the high rates of cross-contamination, cluster-randomized trials may be of particular value⁶⁹.

Probiotics are not without risk, particularly in vulnerable populations such as premature infants. Oversight of production of probiotic products varies from country to country. In the U.S. most commercial probiotics are marketed as dietary supplements with no claims of prevention, treatment, or mitigation of disease. Several studies have demonstrated that most commercial products have limited reliability in terms of purity, composition and numbers of live organisms^{102, 103}. Observations of cross-contamination among infants within a NICU suggest that results of RCTs may be blunted by colonization of the probiotic in the placebo infants^{104, 105}. Even more concerning are rare reports of contamination of commercial probiotics with pathogenic microbes; a recent such case resulted in the death of a premature infant¹⁰⁶. Sepsis cases resulting from translocation of ingested probiotics into the systemic circulation are rare but have been reported for many probiotic species¹⁰⁷⁻¹⁰⁹.

Prebiotics

Prebiotics are non-digestible dietary products that selectively stimulate the growth or activity of beneficial commensal bacteria^{110, 111}. The most commonly administered prebiotics include lactulose, inulin, polydextrose, short-chain (sc) and long-chain (lc) fructo-oligosaccharides and galacto-oligosaccharides, and combinations of the above. The potential complexity of the prebiotic approach to altering the gut microbiota is exemplified by the observations that different isomers of GOS are preferentially consumed by different species of *Bifidobacterium*¹¹² and that some gut pathogens (e.g. *E. coli* EHEC and *C. perfringens*) are able to consume some isomers of GOS¹¹³. Studies in premature infants demonstrate that prebiotics increase fecal *Bifidobacteria*¹¹⁴⁻¹¹⁶, decrease fecal pH^{115, 117, 118}, reduce stool viscosity¹¹⁸, improve gastric motility^{117, 119}, decrease feeding intolerance^{117, 119}, alter production of protective short chain fatty acids¹²⁰, enhance immune response¹²¹, and increase secretory IgA^{119, 122, 123}.

RCTs of prebiotics in premature infants that reported NEC, sepsis or death are summarized in Table 3^{61, 124-127}. Most studies randomized infants and initiated therapy with the first feed or before the third day of life, and duration of therapy was typically until hospital discharge.

A meta-analysis including 7 trials in premature infants found that supplementation with prebiotics increased fecal *Bifidobacteria* and *Lactobacilli*, but did not improve the outcomes of NEC, sepsis or time to full enteral feeding¹¹⁴. Limited follow-up studies of premature infants treated with prebiotic supplements show no significant decrease in allergic or infectious diseases or vaccine response at 12 months of age^{128, 129}. Two possible explanations for the limited efficacy of prebiotics in premature infants include 1) lack of specificity of commercial prebiotics (i.e. both commensal and potentially pathogenic bacteria are able to use some commercial prebiotics as a food source¹¹³) and 2) provision of a targeted prebiotic (food source for a limited number of species) without an inoculation of the associated probiotic commensals may be ineffective in cases of severe dysbiosis as seen in premature infants.

Synbiotics

A synbiotic is a product that contains both a probiotic microbe and a prebiotic substrate. This combination is particularly compelling as competition for food often determines the composition of the microbiota in a given anatomic niche. The challenge in administration of an effective synbiotic may be in the careful selection of both the prebiotic and the probiotic, with the ideal combination likely including a prebiotic that is consumable by specific commensal gut microbes and not by pathogens or pathobionts and a probiotic with desirable mechanisms of protection. RCTs of synbiotics in premature infants are summarized in Table 4^{61, 130, 131}. Future studies of highly specific synbiotic combinations are needed. Human milk is discussed separately, but may represent the quintessential synbiotic given the presence of both prebiotic human milk oligosaccharides and live bacteria.

Lactoferrin

Lactoferrin is a complex molecule found in abundance in human milk with prebiotic¹³², antimicrobial¹³³, and anti-inflammatory properties¹³⁴. In addition lactoferrin may influence the intestinal microbiota by sequestering iron (the competition for iron in the intestinal lumen is fierce as evidenced by the complexity of bacterial products that facilitate iron recruitment¹³⁵). Both bovine lactoferrin and recombinant human lactoferrin have been studied in RCTs in premature infants with and without a probiotic with mixed results (Table 5¹³⁶⁻¹⁴⁰). A recent meta-analysis reported that oral lactoferrin supplementation decreased late onset sepsis (number needed to treat for an additional beneficial (NNTB) 11), NEC (NNTB 20) and all-cause mortality (NNTB 20). Supplementation with both lactoferrin and a probiotic decreased late onset sepsis (NNTB 8) and NEC (NNTB 20) but not all-cause mortality. Oral lactoferrin with or without probiotics decreased fungal sepsis but did not decrease chronic lung disease or length of hospital stay¹⁴¹. Most reports supported administration of lactoferrin as safe in preterm infants^{136, 138}. Some researchers have excluded infants with a family history of cow's milk allergy from trials of bovine lactoferrin¹⁴².

Human milk

Human milk has been described as a tissue (similar to plasma) rather than simply a food source given its incredible complexity. Human milk contains secretory immunoglobulin A, lactoferrin, lysozyme, bile salt-stimulating lipase, growth factors, and human milk

oligosaccharides (HMOs), all of which provide protective benefits that could potentially contribute to a reduction of NEC. The decrease in NEC with provision of human milk seems to be dose related³⁵. As we have already addressed lactoferrin and data on specific activity of most other human milk components are limited, we will focus on HMOs and human milk bacteria.

HMOs are abundant complex sugar molecules that are not digestable by the human intestinal tract due to the lack of glycosidases necessary to cleave the specific linkages that characterize these molecules. The obvious question is why a mother expends tremendous energy at great cost to herself, even in times of famine, to produce molecules that are not a food source for her infant. The partial answer to this compelling question is that HMOs are a potential food source for intestinal microbes (ie a prebiotic)¹⁴³. Testing of a wide variety of gut microbes in culture media with HMOs as the only carbon source has revealed that HMOs are highly specific: only a relatively few species of bifidobacteria and bacteroides are able to consume HMOs¹⁴⁴⁻¹⁴⁶. Evaluation of bacterial genomes has confirmed that only these few species encode the complex array of glycosidases necessary to transport and digest HMOs^{147, 148}. In other words, HMOs and the few bacteria that are able to consume them either represent a marvelously complex co-evolution of human lactation and a select group of commensal bacteria or incredibly clever design. The complexity of HMO production (with variability from woman to woman and within a given woman over time in the numbers and types of HMOs) allows a mother to shape the microbiota of her offspring¹⁴⁹.

Recent studies suggest that some HMO structures are more readily consumed by gut microbes than others^{150, 151} and that some HMOs are absorbed from the gut into the bloodstream and can be detected in plasma¹⁵² with a subset of these structures filtered by the kidneys and detectable in the urine¹⁵³. In addition, mothers who deliver prematurely have a higher degree of variability in production of fucosylated HMOs than mothers who deliver at term¹⁵⁴. This variation among the more than 100 HMOs characterized to date suggests that some HMOs may be more important in shaping the gut microbiota than others. As an example, about 20% of the North American population is homozygous for a common deletion in the FUT2 gene. These individuals are unable to produce a fucosyl transferase that is essential to creation of α 1-2 fucosyl linkages in secreted glycans and have been historically referred to as non-secretors. Non-secretor individuals are at higher risk for some inflammatory diseases of the intestinal tract (e.g. Crohn's disease and celiac disease) and at lower risk for some intestinal infectious diseases (e.g. norovirus and rotavirus)¹⁵⁵⁻¹⁵⁸. Non-secretor mothers are unable to create specific fucosylated HMOs (e.g. 2'fucosyllactose) which appears to influence the intestinal microbiota of their infants¹⁵⁹.

In a rat model, a specific HMO, disialyllacto-N-tetraose (DSLNT) appears to be protective against NEC^{160, 161}. One clinical study indicated that low concentrations of DSLNT in 4-day mother's milk were associated with increased risk of NEC in VLBW premature infants with HIV-infected mothers ($p < 0.05$)¹⁶². These observations suggest that the protective effect of HMOs against NEC may be highly structure-specific.

The questions of whether human milk contains live bacteria and the origin of these bacteria may have particular relevance to the intestinal microbiota of the premature infant.

Historically milk was thought to be sterile until contaminated by bacteria from the mother's skin and the baby's oral cavity. However recent studies of the milk microbiota suggest that some of the microbes present in human milk originate in the mother's gut with transfer likely occurring through the fecal-skin route or through the maternal lymphatic system with gut microbes being shuttled to the breast by dendritic cells or macrophages¹⁶³. Much is yet to be discovered in this area, however studies of manipulation of the mother's intestinal microbiota to improve the health of her infant are promising, particularly in the prevention of allergies and atopic disease¹⁶⁴, necrotizing enterocolitis¹⁶⁵ and preterm labor¹⁶⁶.

Conclusion

The premature infant is particularly vulnerable to NEC and sepsis likely due to the combination of immature immune responses and dysbiosis. Manipulating the composition of the intestinal microbiota and expression of gut microbial genes is a promising strategy which impacts both of these factors. Among the interventions reviewed, human milk, probiotics, and lactoferrin are currently the most promising. Second generation probiotics, selected based on specific mechanisms of action and/or bacterial genomic sequence and produced at high standards of purity and viability are high priorities. Given that none of the current approaches completely eliminates NEC, further clinical trials and cohort studies of novel probiotics or probiotic combinations for mother and/or baby, combinations of lactoferrin and novel probiotics, and individualized supplementation of human milk with deficient components (e.g. specific HMO or sIgA molecules) in premature infants are indicated.

Acknowledgements

MAU has received funding support from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health, Bethesda Maryland (grant number R01HD059127) and the National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda Maryland (grant number UL1 TR000002). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Neu J, Walker WA. Necrotizing enterocolitis. *N Engl J Med*. 2011; 364:255–64. [PubMed: 21247316]
2. Dominguez KM, Moss RL. Necrotizing enterocolitis. *Clin Perinatol*. 2012; 39:387–401. [PubMed: 22682387]
3. McElroy SJ, Underwood MA, Sherman MP. Paneth cells and necrotizing enterocolitis: a novel hypothesis for disease pathogenesis. *Neonatology*. 2013; 103:10–20. [PubMed: 23006982]
4. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg*. 1978; 187:1–7. [PubMed: 413500]
5. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. *Pediatr Clin North Am*. 1986; 33:179–201. [PubMed: 3081865]
6. Johnson TJ, Patel AL, Bigger HR, Engstrom JL, Meier PP. Cost savings of human milk as a strategy to reduce the incidence of necrotizing enterocolitis in very low birth weight infants. *Neonatology*. 2015; 107:271–6. [PubMed: 25765818]
7. Shah TA, Meinen-Derr J, Gratton T, et al. Hospital and neurodevelopmental outcomes of extremely low-birth-weight infants with necrotizing enterocolitis and spontaneous intestinal perforation. *J Perinatol*. 2012; 32:552–8. [PubMed: 22157625]
8. Yee WH, Soraisham AS, Shah VS, et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. *Pediatrics*. 2012; 129:e298–304. [PubMed: 22271701]

9. Salzman NH, Bevins CL. Dysbiosis--a consequence of Paneth cell dysfunction. *Semin Immunol.* 2013; 25:334–41. [PubMed: 24239045]
10. Clevers HC, Bevins CL. Paneth cells: maestros of the small intestinal crypts. *Annu Rev Physiol.* 2013; 75:289–311. [PubMed: 23398152]
11. Morrow AL, Lagomarcino AJ, Schibler KR, et al. Early microbial and metabolomic signatures predict later onset of necrotizing enterocolitis in preterm infants. *Microbiome.* 2013; 1:13. [PubMed: 24450576]
12. Mai V, Young CM, Ukhanova M, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. *PLoS One.* 2011; 6:e20647. [PubMed: 21674011]
13. Berrington JE, Stewart CJ, Cummings SP, Embleton ND. The neonatal bowel microbiome in health and infection. *Curr Opin Infect Dis.* 2014; 27:236–43. [PubMed: 24751892]
14. Cassir N, Benamar S, Khalil JB, et al. Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates. *Clin Infect Dis.* 2015; 61:1107–15. [PubMed: 26084844]
15. Winter SE, Baumler AJ. Dysbiosis in the inflamed intestine: chance favors the prepared microbe. *Gut Microbes.* 2014; 5:71–3. [PubMed: 24637596]
16. Ardisson AN, de la Cruz DM, Davis-Richardson AG, et al. Meconium microbiome analysis identifies bacteria correlated with premature birth. *PLoS One.* 2014; 9:e90784. [PubMed: 24614698]
17. DiGiulio DB, Gervasi M, Romero R, et al. Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. *J Perinat Med.* 2010; 38:503–13. [PubMed: 20482470]
18. DiGiulio DB, Gervasi MT, Romero R, et al. Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. *J Perinat Med.* 2010; 38:495–502. [PubMed: 20482466]
19. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci U S A.* 2010; 107:11971–5. [PubMed: 20566857]
20. Arbolea S, Ang L, Margolles A, et al. Deep 16S rRNA metagenomics and quantitative PCR analyses of the premature infant fecal microbiota. *Anaerobe.* 2012; 18:378–80. [PubMed: 22579986]
21. Arbolea S, Binetti A, Salazar N, et al. Establishment and development of intestinal microbiota in preterm neonates. *FEMS Microbiol Ecol.* 2012; 79:763–72. [PubMed: 22126419]
22. Gomez-Llorente C, Plaza-Diaz J, Aguilera M, et al. Three main factors define changes in fecal microbiota associated with feeding modality in infants. *J Pediatr Gastroenterol Nutr.* 2013; 57:461–6. [PubMed: 23752082]
23. Berrington JE, Stewart CJ, Embleton ND, Cummings SP. Gut microbiota in preterm infants: assessment and relevance to health and disease. *Arch Dis Child Fetal Neonatal Ed.* 2013; 98:F286–90. [PubMed: 23009761]
24. Jakobsson HE, Abrahamsson TR, Jenmalm MC, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. *Gut.* 2014; 63:559–66. [PubMed: 23926244]
25. Greenwood C, Morrow AL, Lagomarcino AJ, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. *J Pediatr.* 2014; 165:23–9. [PubMed: 24529620]
26. La Rosa PS, Warner BB, Zhou Y, et al. Patterned progression of bacterial populations in the premature infant gut. *Proc Natl Acad Sci U S A.* 2014; 111:12522–7. [PubMed: 25114261]
27. Gupta RW, Tran L, Norori J, et al. Histamine-2 receptor blockers alter the fecal microbiota in premature infants. *J Pediatr Gastroenterol Nutr.* 2013; 56:397–400. [PubMed: 23254444]
28. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. *Pediatrics.* 2006; 117:e137–42. [PubMed: 16390920]
29. Weintraub AS, Ferrara L, Deluca L, et al. Antenatal antibiotic exposure in preterm infants with necrotizing enterocolitis. *J Perinatol.* 2012; 32:705–9. [PubMed: 22157626]

30. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. *J Pediatr.* 2011; 159:720–5. [PubMed: 21784435]
31. Brooks B, Firek BA, Miller CS, et al. Microbes in the neonatal intensive care unit resemble those found in the gut of premature infants. *Microbiome.* 2014; 2:1. [PubMed: 24468033]
32. Sohn K, Kalanetra K, Mills DA, et al. Buccal administration of human colostrum: impact on the oral microbiota. *J Perinatol.* 2015 In press.
33. Wacklin P, Tuimala J, Nikkila J, et al. Faecal microbiota composition in adults is associated with the FUT2 gene determining the secretor status. *PLoS One.* 2014; 9:e94863. [PubMed: 24733310]
34. Morrow AL, Meinzen-Derr J, Huang P, et al. Fucosyltransferase 2 non-secretor and low secretor status predicts severe outcomes in premature infants. *J Pediatr.* 2011; 158:745–51. [PubMed: 21256510]
35. Meinzen-Derr J, Poindexter B, Wrage L, et al. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. *J Perinatol.* 2009; 29:57–62. [PubMed: 18716628]
36. Underwood MA. Intestinal dysbiosis: novel mechanisms by which gut microbes trigger and prevent disease. *Prev Med.* 2014; 65:133–7. [PubMed: 24857830]
37. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. *Evid Based Child Health.* 2014; 9:584–671. [PubMed: 25236307]
38. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. *Pediatrics.* 2010; 126:1217–31. [PubMed: 21115585]
39. Underwood MA, Arriola J, Gerber CW, et al. *Bifidobacterium longum* subsp. *infantis* in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. *Pediatr Res.* 2014; 76:326–33. [PubMed: 25000347]
40. Underwood MA, Kananurak A, Coursodon CF, et al. *Bifidobacterium bifidum* in a rat model of necrotizing enterocolitis: antimicrobial peptide and protein responses. *Pediatr Res.* 2012; 71:546–51. [PubMed: 22322385]
41. Satoh T, Izumi H, Iwabuchi N, et al. *Bifidobacterium breve* prevents necrotising enterocolitis by suppressing inflammatory responses in a preterm rat model. *Benef Microbes.* 2015:1–8. [PubMed: 26420070]
42. Ganguli K, Meng D, Rautava S, et al. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. *Am J Physiol Gastrointest Liver Physiol.* 2013; 304:G132–41. [PubMed: 23139215]
43. Underwood MA, German JB, Lebrilla CB, Mills DA. *Bifidobacterium longum* subspecies *infantis*: champion colonizer of the infant gut. *Pediatr Res.* 2015; 77:229–35. [PubMed: 25303277]
44. Khailova L, Dvorak K, Arganbright KM, et al. *Bifidobacterium bifidum* improves intestinal integrity in a rat model of necrotizing enterocolitis. *Am J Physiol Gastrointest Liver Physiol.* 2009; 297:G940–9. [PubMed: 20501441]
45. Khailova L, Mount Patrick SK, Arganbright KM, et al. *Bifidobacterium bifidum* reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. *Am J Physiol Gastrointest Liver Physiol.* 2010; 299:G1118–27. [PubMed: 20705904]
46. Arboleya S, Salazar N, Solis G, et al. Assessment of intestinal microbiota modulation ability of *Bifidobacterium* strains in in vitro fecal batch cultures from preterm neonates. *Anaerobe.* 2013; 19:9–16. [PubMed: 23154045]
47. Fujii T, Ohtsuka Y, Lee T, et al. *Bifidobacterium breve* enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. *J Pediatr Gastroenterol Nutr.* 2006; 43:83–8. [PubMed: 16819382]
48. Goncalves FL, Soares LM, Figueira RL, et al. Evaluation of the expression of I-FABP and L-FABP in a necrotizing enterocolitis model after the use of *Lactobacillus acidophilus*. *J Pediatr Surg.* 2015; 50:543–9. [PubMed: 25840060]
49. Good M, Sodhi CP, Ozolek JA, et al. *Lactobacillus rhamnosus* HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9. *Am J Physiol Gastrointest Liver Physiol.* 2014; 306:G1021–32. [PubMed: 24742987]

50. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-kappaB signaling in the intestine. *Am J Physiol Gastrointest Liver Physiol*. 2012; 302:G608–17. [PubMed: 22207578]
51. Borthakur A, Bhattacharyya S, Kumar A, et al. Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells. *PLoS One*. 2013; 8:e75664. [PubMed: 24130731]
52. Biersmith B, Wang ZH, Geisbrecht ER. Fine-Tuning of the Actin Cytoskeleton and Cell Adhesion During Drosophila Development by the Unconventional Guanine Nucleotide Exchange Factors Myoblast City and Sponge. *Genetics*. 2015; 200:551–67. [PubMed: 25908317]
53. Liu Y, Fatheree NY, Dingle BM, Tran DQ, Rhoads JM. Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. *PLoS One*. 2013; 8:e56547. [PubMed: 23437165]
54. Kunze WA, Mao YK, Wang B, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. *J Cell Mol Med*. 2009; 13:2261–70. [PubMed: 19210574]
55. Mirpuri J, Sotnikov I, Myers L, et al. Lactobacillus rhamnosus (LGG) regulates IL-10 signaling in the developing murine colon through upregulation of the IL-10R2 receptor subunit. *PLoS One*. 2012; 7:e51955. [PubMed: 23272193]
56. Lin PW, Nasr TR, Berardinelli AJ, Kumar A, Neish AS. The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. *Pediatr Res*. 2008; 64:511–6. [PubMed: 18552706]
57. Patel RM, Myers LS, Kurundkar AR, et al. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. *Am J Pathol*. 2012; 180:626–35. [PubMed: 22155109]
58. Yan F, Polk DB. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. *Gut Microbes*. 2012; 3:25–8. [PubMed: 22356855]
59. Olsen R, Greisen G, Schroder M, Brok J. Prophylactic Probiotics for Preterm Infants: A Systematic Review and Meta-Analysis of Observational Studies. *Neonatology*. 2015; 109:105–12. [PubMed: 26624488]
60. Costeloe K, Hardy P, Juszczak E, Wilks M, Millar MR. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. *Lancet*. 2015
61. Dilli D, Aydin B, Fettah ND, et al. The propre-save study: effects of probiotics and prebiotics alone or combined on necrotizing enterocolitis in very low birth weight infants. *J Pediatr*. 2015; 166:545–51. e1. [PubMed: 25596096]
62. Saengtawesin V, Tangpolkaiwalsak R, Kanjanapattankul W. Effect of oral probiotics supplementation in the prevention of necrotizing enterocolitis among very low birth weight preterm infants. *J Med Assoc Thai*. 2014; 97(Suppl 6):S20–5. [PubMed: 25391168]
63. Tewari VV, Dubey SK, Gupta G. Bacillus clausii for Prevention of Late-onset Sepsis in Preterm Infants: A Randomized Controlled Trial. *J Trop Pediatr*. 2015; 61:377–85. [PubMed: 26246087]
64. Hays S, Jacquot A, Gauthier H, et al. Probiotics and growth in preterm infants: A randomized controlled trial, PREMAPRO study. *Clin Nutr*. 2015 doi: 101016/j.clnu.2015.06.006. [Epub ahead of print].
65. Van Niekerk E, Nel DG, Blaauw R, Kirsten GF. Probiotics Reduce Necrotizing Enterocolitis Severity in HIV-exposed Premature Infants. *J Trop Pediatr*. 2015; 61:155–64. [PubMed: 25724213]
66. Dutta S, Ray P, Narang A. Comparison of stool colonization in premature infants by three dose regimes of a probiotic combination: a randomized controlled trial. *Am J Perinatol*. 2015; 32:733–40. [PubMed: 25519197]
67. Patole S, Keil AD, Chang A, et al. Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial. *PLoS One*. 2014; 9:e89511. [PubMed: 24594833]

68. Oncel MY, Sari FN, Arayici S, et al. Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. *Arch Dis Child Fetal Neonatal Ed.* 2014; 99:F110–5. [PubMed: 24309022]
69. Totsu S, Yamasaki C, Terahara M, Uchiyama A, Kusuda S. Bifidobacterium and enteral feeding in preterm infants: cluster-randomized trial. *Pediatr Int.* 2014; 56:714–9. [PubMed: 24617812]
70. Jacobs SE, Tobin JM, Opie GF, et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. *Pediatrics.* 2013; 132:1055–62. [PubMed: 24249817]
71. Serce O, Benzer D, Gursoy T, Karatekin G, Ovali F. Efficacy of *Saccharomyces boulardii* on necrotizing enterocolitis or sepsis in very low birth weight infants: a randomised controlled trial. *Early Hum Dev.* 2013; 89:1033–6. [PubMed: 24041815]
72. Demirel G, Erdevi O, Celik IH, Dilmen U. *Saccharomyces boulardii* for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled study. *Acta Paediatr.* 2013; 102:e560–5. [PubMed: 24028629]
73. Rojas MA, Lozano JM, Rojas MX, et al. Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. *Pediatrics.* 2012; 130:e1113–20. [PubMed: 23071204]
74. Fernandez-Carrocera LA, Solis-Herrera A, Cabanillas-Ayon M, et al. Double-blind, randomised clinical assay to evaluate the efficacy of probiotics in preterm newborns weighing less than 1500 g in the prevention of necrotising enterocolitis. *Arch Dis Child Fetal Neonatal Ed.* 2013; 98:F5–9. [PubMed: 22556209]
75. Al-Hosni M, Duenas M, Hawk M, et al. Probiotics-supplemented feeding in extremely low-birth-weight infants. *J Perinatol.* 2012; 32:253–9. [PubMed: 21546942]
76. Sari FN, Dizdar EA, Oguz S, et al. Oral probiotics: *Lactobacillus sporogenes* for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial. *Eur J Clin Nutr.* 2011; 65:434–9. [PubMed: 21245887]
77. Braga TD, da Silva GA, de Lira PI, de Carvalho Lima M. Efficacy of *Bifidobacterium breve* and *Lactobacillus casei* oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. *Am J Clin Nutr.* 2011; 93:81–6. [PubMed: 20980486]
78. Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by *Candida* in preterm newborns: incidence of late-onset sepsis and neurological outcome. *J Perinatol.* 2011; 31:63–9. [PubMed: 20410904]
79. Awad H, Mokhtar H, Imam SS, et al. Comparison between killed and living probiotic usage versus placebo for the prevention of necrotizing enterocolitis and sepsis in neonates. *Pak J Biol Sci.* 2010; 13:253–62. [PubMed: 20506712]
80. Mihatsch WA, Vossbeck S, Eikmanns B, Hoegel J, Pohlandt F. Effect of *Bifidobacterium lactis* on the incidence of nosocomial infections in very-low-birth-weight infants: a randomized controlled trial. *Neonatology.* 2010; 98:156–63. [PubMed: 20234140]
81. Samanta M, Sarkar M, Ghosh P, et al. Prophylactic probiotics for prevention of necrotizing enterocolitis in very low birth weight newborns. *J Trop Pediatr.* 2009; 55:128–31. [PubMed: 18842610]
82. Rouge C, Piloquet H, Butel MJ, et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr.* 2009; 89:1828–35. [PubMed: 19369375]
83. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. *Pediatrics.* 2008; 122:693–700. [PubMed: 18829790]
84. Stratiki Z, Costalos C, Sevastiadou S, et al. The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants. *Early Hum Dev.* 2007; 83:575–9. [PubMed: 17229535]
85. Wang C, Shoji H, Sato H, et al. Effects of oral administration of *bifidobacterium breve* on fecal lactic acid and short-chain fatty acids in low birth weight infants. *J Pediatr Gastroenterol Nutr.* 2007; 44:252–7. [PubMed: 17255840]

86. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with *Lactobacillus casei* subspecies *rhamnosus* prevents enteric colonization by *Candida* species in preterm neonates: a randomized study. *Clin Infect Dis*. 2006; 42:1735–42. [PubMed: 16705580]
87. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. *Pediatrics*. 2005; 115:1–4. [PubMed: 15629973]
88. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. *J Pediatr*. 2005; 147:192–6. [PubMed: 16126048]
89. Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of premature infants with *Saccharomyces boulardii*. *Early Hum Dev*. 2003; 74:89–96. [PubMed: 14580749]
90. Dani C, Biadaoli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. *Biol Neonate*. 2002; 82:103–8. [PubMed: 12169832]
91. Reuman PD, Duckworth DH, Smith KL, et al. Lack of effect of *Lactobacillus* on gastrointestinal bacterial colonization in premature infants. *Pediatr Infect Dis*. 1986; 5:663–8. [PubMed: 3099269]
92. Dang S, Shook L, Garlitz K, Hanna M, Desai N. Nutritional outcomes with implementation of probiotics in preterm infants. *J Perinatol*. 2015; 35:447–50. [PubMed: 25590220]
93. Repa A, Thanhaeuser M, Endress D, et al. Probiotics (*Lactobacillus acidophilus* and *Bifidobacterium bifidum*) prevent NEC in VLBW infants fed breast milk but not formula. *Pediatr Res*. 2015; 77:381–8. [PubMed: 25423074]
94. Hartel C, Pagel J, Rupp J, et al. Prophylactic use of *Lactobacillus acidophilus*/*Bifidobacterium infantis* probiotics and outcome in very low birth weight infants. *J Pediatr*. 2014; 165:285–9. e1. [PubMed: 24880888]
95. Janvier A, Malo J, Barrington KJ. Cohort study of probiotics in a North American neonatal intensive care unit. *J Pediatr*. 2014; 164:980–5. [PubMed: 24411521]
96. Bonsante F, Iacobelli S, Gouyon JB. Routine probiotic use in very preterm infants: retrospective comparison of two cohorts. *Am J Perinatol*. 2013; 30:41–6. [PubMed: 22773285]
97. Li D, Rosito G, Slagle T. Probiotics for the prevention of necrotizing enterocolitis in neonates: an 8-year retrospective cohort study. *J Clin Pharm Ther*. 2013; 38:445–9. [PubMed: 23865733]
98. Hunter C, Dimaguila MA, Gal P, et al. Effect of routine probiotic, *Lactobacillus reuteri* DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight < 1000 grams: a sequential analysis. *BMC Pediatr*. 2012; 12:142. [PubMed: 22947597]
99. Luoto R, Matomaki J, Isolauri E, Lehtonen L. Incidence of necrotizing enterocolitis in very-low-birth-weight infants related to the use of *Lactobacillus GG*. *Acta Paediatr*. 2010; 99:1135–8. [PubMed: 20219023]
100. Yamashiro Y, Nagata S. Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy. *Benef Microbes*. 2010; 1:357–65. [PubMed: 21831775]
101. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of *Lactobacillus acidophilus* and *Bifidobacterium infantis* to neonates in an intensive care unit. *Int J Infect Dis*. 1999; 3:197–202. [PubMed: 10575148]
102. Lewis ZT, Shani G, Masarweh C, et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. *Pediatr Res*. 2015
103. Marcobal A, Underwood MA, Mills DA. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. *J Pediatr Gastroenterol Nutr*. 2008; 46:608–11. [PubMed: 18493222]
104. Hickey L, Garland SM, Jacobs SE, O'Donnell CP, Tabrizi SN. Cross-colonization of infants with probiotic organisms in a neonatal unit. *J Hosp Infect*. 2014; 88:226–9. [PubMed: 25447201]
105. Underwood MA, Kalanetra KM, Bokulich NA, et al. A comparison of two probiotic strains of bifidobacteria in premature infants. *J Pediatr*. 2013; 163:1585–91. e9. [PubMed: 23993139]
106. Vallabhaneni S, Walker TA, Lockhart SR, et al. Notes from the field: Fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement--Connecticut, 2014. *MMWR Morb Mortal Wkly Rep*. 2015; 64:155–6. [PubMed: 25695322]
107. Bertelli C, Pilonel T, Torregrossa A, et al. *Bifidobacterium longum* bacteremia in preterm infants receiving probiotics. *Clin Infect Dis*. 2015; 60:924–7. [PubMed: 25472946]

108. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. *J Pediatr*. 2010; 156:679–81. [PubMed: 20303445]
109. Thompson C, McCarter YS, Krause PJ, Herson VC. Lactobacillus acidophilus sepsis in a neonate. *J Perinatol*. 2001; 21:258–60. [PubMed: 11533845]
110. Panigrahi P. Probiotics and prebiotics in neonatal necrotizing enterocolitis: New opportunities for translational research. *Pathophysiology*. 2014; 21:35–46. [PubMed: 24594006]
111. Hutkins RW, Krumbeck JA, Bindels LB, et al. Prebiotics: why definitions matter. *Curr Opin Biotechnol*. 2015; 37:1–7. [PubMed: 26431716]
112. Peacock KS, Ruhaak LR, Tsui MK, Mills DA, Lebrilla CB. Isomer-specific consumption of galactooligosaccharides by bifidobacterial species. *J Agric Food Chem*. 2013; 61:12612–9. [PubMed: 24313277]
113. Makelainen H, Saarinen M, Stowell J, Rautonen N, Ouwehand AC. Xylo oligosaccharides and lactitol promote the growth of Bifidobacterium lactis and Lactobacillus species in pure cultures. *Benef Microbes*. 2010; 1:139–48. [PubMed: 21840802]
114. Srinivasjois R, Rao S, Patole S. Prebiotic supplementation in preterm neonates: updated systematic review and meta-analysis of randomised controlled trials. *Clin Nutr*. 2013; 32:958–65. [PubMed: 23786897]
115. Westerbeek EA, Slump RA, Lafeber HN, et al. The effect of enteral supplementation of specific neutral and acidic oligosaccharides on the faecal microbiota and intestinal microenvironment in preterm infants. *Eur J Clin Microbiol Infect Dis*. 2013; 32:269–76. [PubMed: 22961006]
116. Barrett E, Deshpandey AK, Ryan CA, et al. The neonatal gut harbours distinct bifidobacterial strains. *Arch Dis Child Fetal Neonatal Ed*. 2015; 100:F405–10. [PubMed: 25896967]
117. Indrio F, Riezzo G, Raimondi F, et al. Prebiotics improve gastric motility and gastric electrical activity in preterm newborns. *J Pediatr Gastroenterol Nutr*. 2009; 49:258–61. [PubMed: 19561548]
118. Westerbeek EA, Hensgens RL, Mihatsch WA, et al. The effect of neutral and acidic oligosaccharides on stool viscosity, stool frequency and stool pH in preterm infants. *Acta Paediatr*. 2011; 100:1426–31. [PubMed: 21449921]
119. Roberfroid M, Gibson GR, Hoyle L, et al. Prebiotic effects: metabolic and health benefits. *Br J Nutr*. 2010; 104(Suppl 2):S1–63. [PubMed: 20920376]
120. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. *Nature*. 2011; 469:543–7. [PubMed: 21270894]
121. Seifert S, Watzl B. Inulin and oligofructose: review of experimental data on immune modulation. *J Nutr*. 2007; 137:2563S–7S. [PubMed: 17951503]
122. Vandenplas Y, Zakharova I, Dmitrieva Y. Oligosaccharides in infant formula: more evidence to validate the role of prebiotics. *Br J Nutr*. 2015; 113:1339–44. [PubMed: 25989994]
123. Holscher HD, Faust KL, Czerkies LA, et al. Effects of prebiotic-containing infant formula on gastrointestinal tolerance and fecal microbiota in a randomized controlled trial. *JPEN J Parenter Enteral Nutr*. 2012; 36:95S–105S. [PubMed: 22237884]
124. Armanian AM, Sadeghnia A, Hoseinzadeh M, et al. The Effect of Neutral Oligosaccharides on Reducing the Incidence of Necrotizing Enterocolitis in Preterm infants: A Randomized Clinical Trial. *Int J Prev Med*. 2014; 5:1387–95. [PubMed: 25538834]
125. Riskin A, Hochwald O, Bader D, et al. The effects of lactulose supplementation to enteral feedings in premature infants: a pilot study. *J Pediatr*. 2010; 156:209–14. [PubMed: 19879595]
126. Modi N, Uthaya S, Fell J, Kulinskaya E. A randomized, double-blind, controlled trial of the effect of prebiotic oligosaccharides on enteral tolerance in preterm infants (ISRCTN77444690). *Pediatr Res*. 2010; 68:440–5. [PubMed: 20639792]
127. Westerbeek EA, van den Berg JP, Lafeber HN, et al. Neutral and acidic oligosaccharides in preterm infants: a randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr*. 2010; 91:679–86. [PubMed: 20032496]
128. Niele N, van Zwol A, Westerbeek EA, Lafeber HN, van Elburg RM. Effect of non-human neutral and acidic oligosaccharides on allergic and infectious diseases in preterm infants. *Eur J Pediatr*. 2013; 172:317–23. [PubMed: 23132642]

129. van den Berg JP, Westerbeek EA, van der Klis FR, et al. Neutral and acidic oligosaccharides supplementation does not increase the vaccine antibody response in preterm infants in a randomized clinical trial. *PLoS One*. 2013; 8:e70904. [PubMed: 23951035]
130. Nandhini LP, Biswal N, Adhisivam B, et al. Synbiotics for decreasing incidence of necrotizing enterocolitis among preterm neonates - a randomized controlled trial. *J Matern Fetal Neonatal Med*. 2015:1–5.
131. Underwood MA, Salzman NH, Bennett SH, et al. A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. *J Pediatr Gastroenterol Nutr*. 2009; 48:216–25. [PubMed: 19179885]
132. Tian H, Maddox IS, Ferguson LR, Shu Q. Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. *Biometals*. 2010; 23:593–6. [PubMed: 20217186]
133. Lonnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. *Annu Rev Nutr*. 1995; 15:93–110. [PubMed: 8527233]
134. Sherman MP, Miller MM, Sherman J, Niklas V. Lactoferrin and necrotizing enterocolitis. *Curr Opin Pediatr*. 2014; 26:146–50. [PubMed: 24503532]
135. Holden VI, Bachman MA. Diverging roles of bacterial siderophores during infection. *Metallomics*. 2015; 7:986–95. [PubMed: 25745886]
136. Kaur G, Gathwala G. Efficacy of Bovine Lactoferrin Supplementation in Preventing Late-onset Sepsis in low Birth Weight Neonates: A Randomized Placebo-Controlled Clinical Trial. *J Trop Pediatr*. 2015; 61:370–6. [PubMed: 26224129]
137. Ochoa TJ, Zegarra J, Cam L, et al. Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g. *Pediatr Infect Dis J*. 2015; 34:571–6. [PubMed: 25973934]
138. Akin IM, Atasay B, Dogu F, et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. *Am J Perinatol*. 2014; 31:1111–20. [PubMed: 24839144]
139. Manzoni P, Meyer M, Stolfi I, et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. *Early Hum Dev*. 2014; 90(Suppl 1):S60–5. [PubMed: 24709463]
140. Sherman MP, Niklas V, Radmacher P, et al. A clinical trial of talactoferrin to reduce infection in very preterm infants: safety and efficacy. *Pediatric Academic Societies; Washington, D.C.*: May 4-7. 2013
141. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. *Cochrane Database Syst Rev*. 2015; 2:CD007137. [PubMed: 25699678]
142. Turin CG, Zea-Vera A, Pezo A, et al. Lactoferrin for prevention of neonatal sepsis. *Biometals*. 2014; 27:1007–16. [PubMed: 24935001]
143. Smilowitz JT, Lebrilla CB, Mills DA, German JB, Freeman SL. Breast milk oligosaccharides: structure-function relationships in the neonate. *Annu Rev Nutr*. 2014; 34:143–69. [PubMed: 24850388]
144. Ruiz-Moyano S, Totten SM, Garrido DA, et al. Variation in consumption of human milk oligosaccharides by infant gut-associated strains of *Bifidobacterium breve*. *Appl Environ Microbiol*. 2013; 79:6040–9. [PubMed: 23892749]
145. Garrido D, Dallas DC, Mills DA. Consumption of human milk glycoconjugates by infant-associated bifidobacteria: mechanisms and implications. *Microbiology*. 2013; 159:649–64. [PubMed: 23460033]
146. Kim JH, An HJ, Garrido D, et al. Proteomic analysis of *Bifidobacterium longum* subsp. *infantis* reveals the metabolic insight on consumption of prebiotics and host glycans. *PLoS One*. 2013; 8:e57535. [PubMed: 23469017]
147. Sela DA, Garrido D, Lerno L, et al. *Bifidobacterium longum* subsp. *infantis* ATCC 15697 alpha-fucosidases are active on fucosylated human milk oligosaccharides. *Appl Environ Microbiol*. 2012; 78:795–803. [PubMed: 22138995]

148. LoCascio RG, Desai P, Sela DA, Weimer B, Mills DA. Broad conservation of milk utilization genes in *Bifidobacterium longum* subsp. *infantis* as revealed by comparative genomic hybridization. *Appl Environ Microbiol*. 2010; 76:7373–81. [PubMed: 20802066]
149. Underwood MA. Human milk for the premature infant. *Pediatr Clin North Am*. 2013; 60:189–207. [PubMed: 23178065]
150. Underwood MA, Gaerlan S, De Leoz ML, et al. Human milk oligosaccharides in premature infants: absorption, excretion, and influence on the intestinal microbiota. *Pediatr Res*. 2015
151. Garrido D, Ruiz-Moyano S, Lemay DG, et al. Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of infant gut-associated bifidobacteria. *Sci Rep*. 2015; 5:13517. [PubMed: 26337101]
152. Ruhaak LR, Stroble C, Underwood MA, Lebrilla CB. Detection of milk oligosaccharides in plasma of infants. *Anal Bioanal Chem*. 2014; 406:5775–84. [PubMed: 25059723]
153. De Leoz ML, Wu S, Strum JS, et al. A quantitative and comprehensive method to analyze human milk oligosaccharide structures in the urine and feces of infants. *Anal Bioanal Chem*. 2013; 405:4089–105. [PubMed: 23468138]
154. De Leoz ML, Gaerlan SC, Strum JS, et al. Lacto-N-tetraose, fucosylation, and secretor status are highly variable in human milk oligosaccharides from women delivering preterm. *J Proteome Res*. 2012; 11:4662–72. [PubMed: 22900748]
155. Tong M, McHardy I, Ruegger P, et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. *ISME J*. 2014; 8:2193–206. [PubMed: 24781901]
156. Parmar AS, Alakulppi N, Paavola-Sakki P, et al. Association study of FUT2 (rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. *Tissue Antigens*. 2012; 80:488–93. [PubMed: 23075394]
157. Payne DC, Currier RL, Staat MA, et al. Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. *JAMA Pediatr*. 2015; 169:1040–5. [PubMed: 26389824]
158. Currier RL, Payne DC, Staat MA, et al. Innate Susceptibility to Norovirus Infections Influenced by FUT2 Genotype in a United States Pediatric Population. *Clin Infect Dis*. 2015; 60:1631–8. [PubMed: 25744498]
159. Lewis ZT, Totten SM, Smilowitz JT, et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. *Microbiome*. 2015; 3:13. [PubMed: 25922665]
160. Jantscher-Krenn E, Zharebtsov M, Nissan C, et al. The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotizing enterocolitis in neonatal rats. *Gut*. 2012; 61:1417–25. [PubMed: 22138535]
161. Yu H, Lau K, Thon V, et al. Synthetic disialyl hexasaccharides protect neonatal rats from necrotizing enterocolitis. *Angew Chem Int Ed Engl*. 2014; 53:6687–91. [PubMed: 24848971]
162. Van Niekerk E, Autran CA, Nel DG, et al. Human milk oligosaccharides differ between HIV-infected and HIV-uninfected mothers and are related to necrotizing enterocolitis incidence in their preterm very-low-birth-weight infants. *J Nutr*. 2014; 144:1227–33. [PubMed: 24919691]
163. Jeurink PV, van Bergenhenegouwen J, Jimenez E, et al. Human milk: a source of more life than we imagine. *Benef Microbes*. 2013; 4:17–30. [PubMed: 23271066]
164. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. *J Allergy Clin Immunol*. 2012; 130:1355–60. [PubMed: 23083673]
165. Benor S, Marom R, Ben Tov A, et al. Probiotic supplementation in mothers of very low birth weight infants. *Am J Perinatol*. 2014; 31:497–504. [PubMed: 23934538]
166. Jacob JA. Another Frontier in Microbiome Research: Preterm Birth. *JAMA*. 2015; 314:1550–1. [PubMed: 26418197]

Figure 1. Dietary and supplemental strategies for altering the intestinal microbiota of the premature infant. Shading represents areas of overlap.

Table 1

Summary of probiotic RCTs in premature infants

Author Year	Country	Probiotic Species (strain)	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths	
						Prob	Cont	Prob	Cont	Prob	Cont	Prob	Cont
Costeloe 2015 ⁶⁰	UK	B breve (BBG 001)	NR (Yakult)	GA 23-30w	1.6e8-1.6e9/d until 36w	650	660	62	66	73	77	54	56
Dilli 2015 ⁶¹	Turkey	B lactis (NR)	Maflor (Mamse I)	BW < 1500g + GA < 32w	5e9/d × 8w	100	100	2	18	8	13	3	12
Saengtaewes in 2015 ⁶²	Thailand	L acidophilus + B bifida (NR)	Infloran (NR)	BW < 1500g + GA < 34w	2e9 BID × 6w	31	29	1	1	2	1	0	0
Tewari 2015 ⁶³	India	Bacillus clausii (NR)	Enterogermina (Sanofi Aventis)	GA < 34w	8e8 TID × 3-5w	123	121	0	0	20	25	12	14
Hays 2015 ⁶⁴	France	B lactis + B longum(NR)	NR	BW 700-1600g + GA 25-31w	1e9/d × 4-6w	48	52	5	3	8	10	1	1
		B lactis (NR)				50		2		9		1	
		B longum (NR)				49		1		8		3	
Van Niekirk 2015 ⁶⁵	South Africa	B infantis (NR) + L rhamnosus (GG)	Pro-B2 (C Pharm)	BW < 1250g	7e8/d × 28d	91	93	0	4	15	10	5	7
Dutta 2015 ⁶⁶	India	L acidophilus + L rhamnos	NR (Aristo)	GA 27-33 w	1e10 BID × 21d us + B longum + S boulardii (NR)	38	35	1	0	3	6	3	2
					1e10 BID × 14d	38		3		1		3	
					1e9 BID × 21d	38		2		6		2	
Patole 2014 ⁶⁷	Australia	B breve (M-16V)	NR (Morinaga)	BW < 1500g + GA < 33w	3e9/d until 37w	79	80	0	1	17	12	0	0
Oncel 2014 ⁶⁸	Turkey	L reuteri (DSM 17938)	NR (Biogaia AB)	BW < 1500g + GA < 32w	1e8/d until discharge	200	200	8	10	13	25	15	20
Totsu 2014 ⁶⁹	Japan	B bifidum (OLB 6378)	NR (Meiji)	BW < 1500g	1.25e 9 BID until > 2kg	153	130	0	0	6	10	2	0
Jacobs 2013 ⁷⁰	Australia + NZ	B infantis (BB-02) + S thermophilus (TH-415957) + B lactis (BB-1215954)	ABC Dophilus (Solgar)	BW < 1500g + GA < 32w	1e9/d until discharge	548	551	11	24	72	89	27	28
Serce 2013 ⁷¹	Turkey	Saccharomyces boulardii (NR)	Reflor (Biocodex)	BW < 1500g + GA < 32w	5e8/kg BID until discharge	104	104	7	7	72	89	27	28
Demirel 2013 ⁷²	Turkey	Saccharomyces boulardii (NR)	Reflor (Biocodex)	BW < 1500g + GA < 32w	5e9/kg BID until discharge	135	136	6	7	20	21	5	5
Rojas 2012 ⁷³	Colombia	L reuteri(DSM 17938)	NR (Biogaia AB)	BW < 2000g	1e8/d until discharge	372	378	9	15	24	17	22	28

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Author Year	Country	Probiotic Species (strain)	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths	
						Prob	Cont	Prob	Cont	Prob	Cont	Prob	Cont
Fernandez-Carrocera 2012 ⁷⁴	Mexico	L acidophilus + L rhamnosus + L casei + L plantarum + B infantis + S thermophilus (NR)	107M96 y 106M96 (Italmex)	BW < 1500g	3e9/d (NR)	75	75	6	12	NR	NR	1	7
Al-Hosni 2012 ⁷⁵	USA	B infantis (NR) + L rhamnosus (GG)	Align (Proctor and Gamble) + Culturelle (Amerifit)	BW 501-1000g	1e9/d until 34w	50	50	2	2	13	16	3	4
Sari 2011 ⁷⁶	Turkey	L sporogenes (NR)	NR (DMG Italia)	BW < 1500g or GA <33w	3.5e8/d (NR)	110	111	6	10	NR	NR	3	4
Braga 2011 ⁷⁷	Brazil	L casei + B breve (NR)	NR (Yakult)	BW 750-1499g	3.5e7-3.5e9/d × 28d	119	112	0	4	NR	NR	26	27
Romeo 2011 ⁷⁸	Italy	L reuteri (ATCC 55730)	NR	BW < 2500g + GA < 37w	1e8/d until discharge	83	83	NR	NR	1	9	NR	NR
		L rhamnosus (ATCC 53103)	NR		6e9/d until discharge	83	83	NR	NR	2	NR	NR	NR
Awad 2010 ⁷⁹	Egypt	L rhamnosus (GG)	Lacteol Fort (Axean)	GA 28-41w	6e9 BID until discharge	60	30	0	5	NR	NR	NR	NR
		Killed L rhamnosus (GG)				60	60	1	NR	NR	NR	NR	NR
Mihatsch 2010 ⁸⁰	Germany	B lactis (BB12)	NR (Nestle)	BW < 1500g + GA < 30w	2e9/kg q 4h × 6w	91	89	2	4	28	29	2	1
Samanta 2009 ⁸¹	India	B longum + B infantis + B bifidum + L acidophilus (NR)	NR	BW < 1500g + GA < 32w	1e10 BID until discharge	91	95	5	15	13	28	4	14
Rouge 2009 ⁸²	France	B longum (BB536) + L rhamnosus (GG)	NR (Morina + Valio)	BW < 1500g + GA < 32w	1e8 QID until discharge	45	49	2	1	15	13	2	4
Lin 2008 ⁸³	Taiwan	L acidophilus (NCDO 1748) + B bifidum (NCDO 1453)	Inflozan (Laboratorio Farmaceutico)	BW < 1500g + GA < 34w	1e9 BID until 6w	217	217	4	14	40	24	2	9
Stratiki 2007 ⁸⁴	Greece	B lactis (NR)	Prenan (Nestle)	GA 27-37w	varied with feeding volume × 30d	41	36	0	3	0	3	NR	NR
Wang 2007 ⁸⁵	Japan	B breve (M-16V)	NR (Morinaga)	GA 23-36w	1.6e8 BID until discharge	33	33	0*	0*	0	0	NR	NR
Manzoni 2006 ⁸⁶	Italy	L rhamnosus (GG)	Dicoflor 60 (Dicofarm)	BW < 1500g	6e9/d until 6w	39	41	1	3	19	22	5	6
Fujii 2006 ⁴⁷	Japan	B breve (M-16V)	NR (Morinaga)	GA 31w (SD 3w)	1e9 BID until discharge	11	8	0	0	1	1	NR	NR
Lin 2005 ⁸⁷	Taiwan	L acidophilus + B infantis (NR)	Inflozan (Swiss Serum and Vaccine Institute)	BW < 1500g	1e9 BID until discharge	180	187	2	10	22	36	7	20
Bin-Nun 2005 ⁸⁸	Israel	B infantis + S thermophilus + B lactis (NR)	ABC Dophilus (Solgar)	BW < 1500g	1e9/d until 36w	72	72	1	10	NR	NR	3	8
Costalos 2003 ⁸⁹	Greece	Saccharomyces boulardii (NR)	NR	GA 28-32w	1e9/d × 30d	51	36	5	6	3	3	NR	NR
Dani 2002 ⁹⁰	Italy	L rhamnosus (GG)	Dicoflor (Dicofarm)	BW < 1500g + GA < 33w	6e9/d until discharge	295	290	4	8	14	12	0	2

Author Year	Country	Probiotic Species (strain)	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths	
						Prob	Cont	Prob	Cont	Prob	Cont	Prob	Cont
Reuman 1986 ⁹¹	USA	L acidophilus (NR)	NR	BW < 2000g	1e8 BID until discharge	15	15	NR	NR	NR	NR	1	3
					Total	4668	4298	161	263	548	601	244	310
					% of reported	100	100	3.59	6.26	13.18	15.48	5.75	7.62

NR: not reported, BW: birth weight, GA: gestational age, g: grams, w: weeks, d: days

1.6e8: 1.6×10⁸ organisms

* number of NEC cases obtained by personal communication with the author

Table 2

Summary of probiotic cohort studies in premature infants

Author Year	Country	Probiotic Species (strain)	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths	
						Prob	Cont	Prob	Cont	Prob	Cont	Prob	Cont
Dang 2015 ⁹²	USA	L rhamnosus (GG) + B infantis (NR)	Culturelle (Amerifit) + Align (Proctor and Gamble)	BW < 1250g and/or GA < 28w	1e9/d until 34w	128	135	2	8	NR	NR	19	21
Repa 2015 ⁹³	Austria	L acidophilus + B infantis(NR)	Infloran (Laboratoriofarmaceutico)	BW < 1500g	2e9 BID (NR)	230	233	16	24	60	78	16	30
Hartel 2014 ⁹⁴	Germany	L acidophilus + B infantis(NR)	Infloran (Berna)	BW < 1500g + GA < 32w	1e9/d × 14d	3789	1562	116*	76*	428	195	292	160
Janvier 2014 ⁹⁵	Canada	B bifidum + B breve + B infantis + B longum + L rhamnosus (NR + GG)	FloraBA BY (Renew Life)	GA < 32w	2e9/d until 34w	294	317	16	31	54	57	20	31
Bonsante 2013 ⁹⁶	France	L rhamnosus (LCR35)	Lcr Restituo (Probionov)	GA 24-31w	2e8 BID until 36w	347	783	4	41	37	130	8	38
Li 2013 ⁹⁷	USA	B bifidum + B infantis + S thermophilus	NR	BW < 1500g	NR	291	289	7	8	NR	NR	4	3
Hunter 2012 ⁹⁸	USA	L reuteri (DSM 17938)	BioGaia (BioGaia)	BW < 1000g	5.5e7/d until 40w	79	232	2	35	19	72	NR	NR
Luoto 2010 ⁹⁹	Finland	L rhamnosus (GG)	NR	BW < 1500g	6e9/d until discharge	418	1900	19	61	NR	NR	NR	NR
Yamashiro 2010 ¹⁰⁰	Japan	B breve (M-16 V)	NR	BW < 1500g	1e9/d (NR)	338	226	0	6	70	65	39	38
Hoyos 1999 ¹⁰¹	Colombia	L acidophilus + B infantis	Infloran	All NICU admit	5e8/d (NR)	1237	1282	34	85	69	70	137	140
						Total		100	100	11.67	14.37	8.04	9.55
						% of reported		1.40	4.30	737	667	535	461

NR: not reported, BW: birth weight, GA: gestational age, g: grams, w: weeks, d: days

2e9: 2×10⁹ organisms, Prob: probiotic, Cont: control

* Only surgical NEC reported

Table 3

Summary of prebiotic RCTs in premature infants

Author Year	Country	Prebiotic (composition)	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths	
						Preb	Cont	Preb	Cont	Preb	Cont	Preb	Cont
Dilli 2015 ⁶¹	Turkey	Inulin	Mafkor (Mamsel)	BW < 1500g + GA < 32w	900mg/d until discharge	100	100*	12	18*	10	13*	2	12*
Armanian 2014 ¹²⁴	Iran	scGOS:lcf OS(9:1)	NR (Nutricia MMP)	BW < 1500g + GA < 34w	varied with feeding volume	25	50	1	11	4	17	1	1
Riskin 2010 ¹²⁵	Israel	1% lactulose	Laevo lac, (Fresenius Kabi)	GA 23-34w	1g/100 ml each feed until discharge	15	13	1	2	2	4	0	1
Modi 2010 ¹²⁶	UK	scGOS:lcf OS (9:1)	NR (Danone)	GA < 33w	0.8g/10 ml(of formula feedings only)	73	81	2	1	9	10	2	1
Westerbeek 2010 ¹²⁷	Netherlands	80% scGOS/lcf OS + 20% AOS	NR	BW < 1500g and/or GA < 32w	1.5g/kg/d × 28d	55	58	10	6	32	48	2	3
					total	268	302	26	38	57	92	7	18
					% of reported	100	100	9.70	12.58	21.27	30.46	2.61	5.96

NR: not reported, BW: birth weight, GA: gestational age, g: grams, w: weeks, d: days

scGOS: short-chain galacto-oligosaccharides, lcfOS: long-chain fructo-oligosaccharides, AOS: acidic oligosaccharides

* Same control group as reported in Table 1

Table 4

Summary of synbiotic RCTs in premature infants

Author Year	Country	Synbiotic	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths						
						Synb	Cont	Synb	Cont	Synb	Cont	Synb	Cont					
Dilli 2015 ⁶¹	Turk	Inulin + B lactis	Maflor (Mamsel)	BW < 1500g + GA < 32w	inulin 900 mg + 5e9/d × 8w	100	100*	4	18*	8	13*	3	12*					
Nandhini 2015 ¹³⁰	India	Inulin + L acidophilus + LGG + L casei + L plantarum + L bulgaricus + B infantis + B breve + B longum	Prepro HS (Fourtris)	BW > 1000g + GA 28-34w	100 mg/d + 7×10 ⁹ 4×10 ⁹ 3×10 ⁹ 3×10 ⁹ 3×10 ⁹ 4×10 ⁹ BID × 7d	108	110	0	3	4	4	10	9					
Underwood 2009 ¹³¹	USA	Inulin + LGG	ProBio Plus (UAS)	BW 750-2000g + GA < 35w	5e8 BID × 28d or until discharge	30	29	1	1	6	5	0	0					
		31				1		2		0								
		total						269	239	6	22	20	22	13	21			
		% of reported						100	100	2.23	9.20	7.43	9.20	4.83	8.79			

LGG: L rhamnosus (GG), NR: not reported, BW: birth weight, GA: gestational age, g: grams, w: weeks, d: days

5e9: 5×10⁹ organisms

* Same control group as reported in Table 1

Table 5

Summary of lactoferrin RCTs in premature infants

Author Year	Country	Lactoferrin	Brand (Company)	Population	Dose × duration	Number enrolled		NEC cases Stage 2, 3		Culture + sepsis cases		Deaths	
						Lact	Cont	Lact	Cont	Lact	Cont	Lact	Cont
Kaur 2015 ¹³⁶	India	bLF	apolactoferrin (NR)	BW < 2000g	varied with BW × 28d	63	67	NR	NR	2	9	0	5
Ochoa 2015 ¹³⁷	Peru	bLF	NR (Tatua)	BW < 2500g	200mg/kg/d divided 3 doses × 28d	95	95	NR	NR	4	4	7	3
Akin 2014 ¹³⁸	Turk	bLF	LF100 (Dicofarm)	BW < 1500g + GA < 32w	200mg/d until discharge	22	25	0	5	4	8	0	1
Manzoni 2014 ¹³⁹	Italy	bLF	LF100 (Dicofarm)	BW < 1500g	100mg/d × 30d BW > 1000g × 45d BW < 1000g	247	258	5	14	NR	NR	5	18
		bLF + LGG	Dicoflor 60 (Dicofarm)		100mg/d + 6e9/d	238		0		NR		9	
Sherman 2013 ^{*140}	USA	talactoferrin	NR	750-1500g	150 mg/kg BID	60	60	NR	NR	4	4	1	1
						725	505	5	19	14	25	22	28
						100	100	0.99	6.71	5.83	10.12	3.03	5.54
						total							
						% of reported							

NR: not reported, BW: birth weight, GA: gestational age, g: grams, w: weeks, d: days

bLF: bovine lactoferrin , LGG: L rhamnosus (GG)

* Abstract only